PLD

107.1

+1.84%↑

DLR

172.24

-0.26%↓

CCI

105

-2%↓

CSGP

96.51

-0.26%↓

WY

25.8

+2.14%↑

PLD

107.1

+1.84%↑

DLR

172.24

-0.26%↓

CCI

105

-2%↓

CSGP

96.51

-0.26%↓

WY

25.8

+2.14%↑

PLD

107.1

+1.84%↑

DLR

172.24

-0.26%↓

CCI

105

-2%↓

CSGP

96.51

-0.26%↓

WY

25.8

+2.14%↑

PLD

107.1

+1.84%↑

DLR

172.24

-0.26%↓

CCI

105

-2%↓

CSGP

96.51

-0.26%↓

WY

25.8

+2.14%↑

PLD

107.1

+1.84%↑

DLR

172.24

-0.26%↓

CCI

105

-2%↓

CSGP

96.51

-0.26%↓

WY

25.8

+2.14%↑

Search

Alexandria Real Estate Equities Inc

Cerrado

SectorInmobiliario

78.2 1.22

Resumen

Variación precio

24h

Actual

Mínimo

76.95

Máximo

78.5

Métricas clave

By Trading Economics

Ingresos

-101M

-62M

Ventas

19M

762M

P/B

Media del Sector

102.987

43.654

BPA

0.51

Rentabilidad por dividendo

6.4

Margen de beneficio

-8.161

Empleados

552

EBITDA

55M

487M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+27.61% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

6.40%

6.00%

Próximas Ganancias

20 oct 2025

Fecha Próximo Dividendo

14 oct 2025

Próxima Fecha de Ex Dividendo

29 sept 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-32M

14B

Apertura anterior

76.98

Cierre anterior

78.2

Noticias sobre sentimiento de mercado

By Acuity

67%

33%

164 / 189 Clasificación en Real estate

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Alexandria Real Estate Equities Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

4 ago 2025, 21:42 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 ago 2025, 21:21 UTC

Ganancias
Principales Movimientos del Mercado

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 ago 2025, 20:45 UTC

Ganancias

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 ago 2025, 19:15 UTC

Principales Movimientos del Mercado

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 ago 2025, 23:41 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 ago 2025, 23:41 UTC

Charlas de Mercado

Nikkei May Rise on Fed Stimulus Hopes

4 ago 2025, 23:28 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

4 ago 2025, 23:28 UTC

Charlas de Mercado

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 ago 2025, 21:30 UTC

Ganancias

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 ago 2025, 21:21 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 ago 2025, 21:18 UTC

Ganancias

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 ago 2025, 20:25 UTC

Charlas de Mercado

India Hits Back Over Russian Oil Purchases -- Market Talk

4 ago 2025, 20:25 UTC

Ganancias

Transocean 2Q Loss $938M >RIG

4 ago 2025, 20:25 UTC

Ganancias

Transocean 2Q Loss/Shr $1.06 >RIG

4 ago 2025, 20:18 UTC

Ganancias

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 ago 2025, 20:15 UTC

Ganancias

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 ago 2025, 20:14 UTC

Ganancias

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 ago 2025, 20:14 UTC

Ganancias

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 ago 2025, 20:14 UTC

Ganancias

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 ago 2025, 20:13 UTC

Ganancias

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 ago 2025, 20:09 UTC

Ganancias

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 ago 2025, 20:06 UTC

Ganancias

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 ago 2025, 19:41 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 ago 2025, 19:28 UTC

Charlas de Mercado

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 ago 2025, 19:07 UTC

Charlas de Mercado

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 ago 2025, 18:27 UTC

Charlas de Mercado

Gold Climbs on Rate Cut Speculation -- Market Talk

Comparación entre iguales

Cambio de precio

Alexandria Real Estate Equities Inc Esperado

Precio Objetivo

By TipRanks

27.61% repunte

Estimación a 12 meses

Media 97 USD  27.61%

Máximo 130 USD

Mínimo 80 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Alexandria Real Estate Equities Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

8 ratings

3

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

73.42 / 75.585Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

No Evidence

Largo Plazo

No Evidence

Sentimiento

By Acuity

164 / 189 Clasificación en Inmobiliario

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Alexandria Real Estate Equities Inc

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche with our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative mega campuses in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of September 30, 2024, Alexandria has a total market capitalization of $33.1 billion and an asset base in North America that includes 41.8 million RSF of operating properties, 5.3 million RSF of Class A/A+ properties undergoing construction, and one committed near-term project expected to commence construction in the next two years. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.